Core Insights - Structure Therapeutics is focused on making transformative medicines accessible to the masses, particularly in the GLP-1 area [3] - The company has three different programs, with aleniglipron being the lead program, which is an oral GLP-1 small molecule believed to be potentially best-in-class [3] - The company plans to have data readouts for its programs ACCESS and ACCESS II by the end of the year [4] Company Programs - Aleniglipron is the lead program, focusing on oral GLP-1 small molecules [3] - The company is developing an oral amylin small molecule, which is noted to be the first of its kind, set to enter clinical trials by the end of the year [4] - Structure Therapeutics is also focusing on multiple oral amylin small molecules, including DACRAs and SARAs, and is emphasizing combinability in its research [4]